| Field | Specification |
|---|---|
| Target | |
| Alternative names | Nuclear receptor subfamily 5 group A member 2; Alpha-1-fetoprotein transcription factor; B1-binding factor; hB1F; CYP7A promoter-binding factor; Hepatocytic transcription factor; Liver receptor homolog 1; LRH-1; NR5A2; B1F; CPF; FTF |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human NR5A2 recombinant protein (Position: K192-A508). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets nuclear receptor subfamily 5 group A member 2 (gene NR5A2) in human samples and is validated for Western blot, IHC, flow cytometry and ELISA. The predicted molecular weight is 61.3 kDa, and the supplier reports an observed band at about 70 kDa.
LRH-1 (NR5A2) is a monomeric DNA-binding nuclear receptor that regulates genes of cholesterol and bile acid metabolism in the liver and intestine. It also supports early embryonic development and pluripotency and is studied in liver and pancreas biology, intestinal steroidogenesis and pancreatic cancer.
| Target | Nuclear receptor subfamily 5 group A member 2 (gene NR5A2; UniProt O00482, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 61.3 kDa |
| Observed MW | 70 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human A549 cells, human Caco-2 cells, human 293T cells, human MCF-7 cells, human K562 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human parotid acinar cells carcinoma tissue, human bladder urothelial carcinoma tissue, human colorectal adenocarcinoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): Caco-2 cells.
Immunogen
Recombinant human NR5A2 fragment (Lys192–Ala508), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places nuclear receptor subfamily 5 group A member 2 in the nucleus and chromosome. Tissue expression noted by UniProt (human): Abundantly expressed in pancreas, less in liver, very low levels in heart and lung. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
